Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics
RARE Price/Volume Stats
| Current price | $50.06 | 52-week high | $68.68 |
| Prev. close | $49.61 | 52-week low | $33.36 |
| Day low | $49.90 | Volume | 53,715 |
| Day high | $51.47 | Avg. volume | 627,771 |
| 50-day MA | $43.86 | Dividend yield | N/A |
| 200-day MA | $42.74 | Market Cap | 3.54B |
RARE Stock Price Chart Interactive Chart >
RARE POWR Grades
- RARE scores best on the Momentum dimension, with a Momentum rank ahead of 78.35% of US stocks.
- The strongest trend for RARE is in Growth, which has been heading up over the past 179 days.
- RARE's current lowest rank is in the Sentiment metric (where it is better than 31.48% of US stocks).
RARE Stock Summary
- The ratio of debt to operating expenses for ULTRAGENYX PHARMACEUTICAL INC is higher than it is for about merely 7.69% of US stocks.
- With a price/sales ratio of 9.22, ULTRAGENYX PHARMACEUTICAL INC has a higher such ratio than 88.45% of stocks in our set.
- With a year-over-year growth in debt of -27.35%, ULTRAGENYX PHARMACEUTICAL INC's debt growth rate surpasses just 12.05% of about US stocks.
- Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are STRO, ALGS, FDMT, VACC, and ONCT.
- RARE's SEC filings can be seen here. And to visit ULTRAGENYX PHARMACEUTICAL INC's official web site, go to www.ultragenyx.com.
RARE Valuation Summary
- In comparison to the median Healthcare stock, RARE's price/sales ratio is 331.82% higher, now standing at 9.5.
- RARE's price/earnings ratio has moved up 18.5 over the prior 113 months.
Below are key valuation metrics over time for RARE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RARE | 2023-05-23 | 9.5 | 16.5 | -5.1 | -5.0 |
| RARE | 2023-05-22 | 9.4 | 16.3 | -5.0 | -5.0 |
| RARE | 2023-05-19 | 9.2 | 16.0 | -4.9 | -4.9 |
| RARE | 2023-05-18 | 9.4 | 16.4 | -5.0 | -5.0 |
| RARE | 2023-05-17 | 9.1 | 15.8 | -4.8 | -4.8 |
| RARE | 2023-05-16 | 8.6 | 15.0 | -4.6 | -4.6 |
RARE Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at -44.85%.
- The year over year price growth rate now stands at -45.72%.
- Its 5 year revenue growth rate is now at 91517.29%.
The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 343.37 | -344.467 | -678.046 |
| 2022-06-30 | 334.314 | -308.771 | -505.938 |
| 2022-03-31 | 331.946 | -296.87 | -470.204 |
| 2021-12-31 | 351.406 | -338.695 | -454.025 |
| 2021-09-30 | 359.559 | -346.803 | -355.578 |
| 2021-06-30 | 359.382 | -349.121 | -351.425 |
RARE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
- RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
- ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.
The table below shows RARE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.234 | 0.955 | -0.414 |
| 2021-03-31 | 0.225 | 0.956 | -0.267 |
| 2020-12-31 | 0.194 | 0.977 | -0.277 |
| 2020-09-30 | 0.174 | 0.973 | -0.420 |
| 2020-06-30 | 0.140 | 0.962 | -0.540 |
| 2020-03-30 | 0.116 | 0.959 | -0.769 |
RARE Price Target
For more insight on analysts targets of RARE, see our RARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $143.67 | Average Broker Recommendation | 1.58 (Moderate Buy) |
Ultragenyx Pharmaceutical Inc. (RARE) Company Bio
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.
Latest RARE News From Around the Web
Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy SummitNOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's chief medical officer, will present at the 2023 Barclays - Gene Editing & Gene Therapy Summit on Wednesday, May 24, 2023, at 8:50 a.m. ET. The live and archived webcast of the panel will be accessible fro |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 810 shares of common stock of the company and 31,690 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by |
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform DosingUltragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome. |
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohortsNOVATO, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has reviewed and agreed to a protocol amendment to the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome that enables the company to harmonize dose ranges in the U.S. with those being used in ex-U.S. cohorts of |
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS RatingUltragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. |
RARE Price Returns
| 1-mo | 15.53% |
| 3-mo | 9.54% |
| 6-mo | 24.62% |
| 1-year | 0.20% |
| 3-year | -33.33% |
| 5-year | -32.10% |
| YTD | 8.05% |
| 2022 | -44.90% |
| 2021 | -39.25% |
| 2020 | 224.12% |
| 2019 | -1.77% |
| 2018 | -6.25% |
Continue Researching RARE
Want to do more research on Ultragenyx Pharmaceutical Inc's stock and its price? Try the links below:Ultragenyx Pharmaceutical Inc (RARE) Stock Price | Nasdaq
Ultragenyx Pharmaceutical Inc (RARE) Stock Quote, History and News - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...